Suven Life Sciences Valuation

Is 530239 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 530239 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate 530239's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 530239's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 530239?

Key metric: As 530239 barely has revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for 530239. This is calculated by dividing 530239's market cap by their current book value.
What is 530239's PB Ratio?
PB Ratio	13.4x
Book	₹1.93b
Market Cap	₹26.34b

530239 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	293.3x
Enterprise Value/EBITDA	-15.5x
PEG Ratio	n/a

Price to Book Ratio vs Peers

How does 530239's PB Ratio compare to its peers?

The above table shows the PB ratio for 530239 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PB	Estimated Growth	Market Cap
Peer Average	3x
TARSONS Tarsons Products	3.3x	27.7%	₹20.9b
DCAL Dishman Carbogen Amcis	0.6x	n/a	₹34.5b
544184 Borosil Scientific	4.1x	n/a	₹16.1b
WINDLAS Windlas Biotech	4.1x	n/a	₹20.0b
530239 Suven Life Sciences	13.4x	n/a	₹26.3b

Price-To-Book vs Peers: 530239 is expensive based on its Price-To-Book Ratio (13.4x) compared to the peer average (3x).

Price to Book Ratio vs Industry

How does 530239's PB Ratio compare vs other companies in the Asian Life Sciences Industry?

2 Companies	Price / Book	Estimated Growth	Market Cap

2 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Book vs Industry: 530239 is expensive based on its Price-To-Book Ratio (13.4x) compared to the Asian Life Sciences industry average (2.2x).

Price to Book Ratio vs Fair Ratio

What is 530239's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

530239 PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio	13.4x
Fair PB Ratio	n/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate 530239's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Caplin Point Laboratories

₹148.3b

Engages in the development, production, marketing, and export of generic pharmaceutical formulations and branded products in India.

CAPLIPOINT

₹1,952.15

-0.09%

60.0%

Bal Pharma

₹2.1b

Manufactures and markets pharmaceutical formulations and active pharmaceutical ingredients (APIs) in India and internationally.

BALPHARMA

₹130.88

14.0%

21.4%

Vilin Bio Med

₹313.9m

Engages in the manufacture and sale of pharmaceutical products in India.

VILINBIO

₹22.50

-4.9%

6.1%